Flow cytometric detection of ewing sarcoma cells in peripheral blood and bone marrow

Pediatric Blood and Cancer

Volumn 54, Issue 1, 2010, Pages 13-18

  DuBois, Steven G ^a   Epling, C Lorrie ^a   Teague, Juli ^a   Matthay, Katherine K ^a   Sinclair, Elizabeth ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CD99; Ewing sarcoma; Flow cytometry

Indexed keywords

CD45 ANTIGEN; CD99 ANTIGEN; CD99 PROTEIN, HUMAN; CELL ADHESION MOLECULE; LEUKOCYTE ANTIGEN; TUMOR MARKER;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CANCER CYTODIAGNOSIS; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EWING SARCOMA; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SARCOMA CELL; STEM CELL; BONE MARROW; BONE TUMOR; CASE CONTROL STUDY; COMPARATIVE STUDY; IMMUNOLOGY; PATHOLOGY; PROGNOSIS; TUMOR EMBOLISM;

ANTIGENS, CD; ANTIGENS, CD45; BONE MARROW; BONE NEOPLASMS; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES; FLOW CYTOMETRY; HUMANS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; SARCOMA, EWING'S; TUMOR MARKERS, BIOLOGICAL;

EID: 73349105936     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22245     Document Type: Article

References (25)

1. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348:694-701.
2. Chan RC, SutowWW, Lindberg RD, et al. Management and results of localized Ewing's sarcoma. Cancer 1979;43:1001-1006.
3. Cangir A,Vietti TJ, Gehan EA, et al. Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing's sarcoma studies. Cancer 1990;66:887-893.
4. Arvand A, Denny CT. Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene 2001;20:5747-5754.
5. Peter M, Magdelenat H, Michon J, et al. Sensitive detection of occult Ewing's cells by the reverse transcriptase-polymerase chain reaction. Br J Cancer 1995;72:96-100.
6. Pfleiderer C, Zoubek A, Gruber B, et al. Detection of tumour cells in peripheral blood and bone marrow from Ewing tumour patients by RT-PCR. Int J Cancer 1995;64:135-139.
7. West DC, Grier HE, Swallow MM, et al. Detection of circulating tumor cells in patients with Ewing's sarcoma and peripheral primitive neuroectodermal tumor. J Clin Oncol 1997;15:583-588.
8. Zoubek A, Ladenstein R, Windhager R, et al. Predictive potential of testing for bone marrow involvement in Ewing tumor patients by RT-PCR: A preliminary evaluation. Int J Cancer 1998;79:56-60.
9. Schleiermacher G, Peter M, Oberlin O, et al. Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized Ewing tumor. J Clin Oncol 2003;21:85-91.
10. Ambros IM, Ambros PF, Strehl S, et al. MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer 1991;67:1886-1893.
11. Dworzak MN, Fritsch G, Buchinger P, et al. Flow cytometric assessment of human MIC2 expression in bone marrow, thymus, and peripheral blood. Blood 1994;83:415-425.
12. Dworzak MN, Froschl G, Printz D, et al. CD99 expression in Tlineage ALL: Implications for flow cytometric detection of minimal residual disease. Leukemia 2004;18:703-708.
13. Chang A, Benda PM, Wood BL, et al. Lineage-specific identi-fication of nonhematopoietic neoplasms by flow cytometry. Am J Clin Pathol 2003;119:643-655.
14. Leon ME, Hou JS, Galindo LM, et al. Fine-needle aspiration of adult small-round-cell tumors studied with flow cytometry. Diagn Cytopathol 2004;31:147-154.
15. Kreppel M, Aryee DN, Schaefer KL, et al. Suppression of KCMF1 by constitutive high CD99 expression is involved in the migratory ability of Ewing's sarcoma cells. Oncogene 2006;25:2795-2800.
16. Martinez-Ramirez A, Rodriguez-Perales S, Melendez B, et al. Characterization of the A673 cell line (Ewing tumor) by molecular cytogenetic techniques. Cancer Genet Cytogenet 2003;141:138-142.
17. Scotlandi K, Baldini N, Cerisano V, et al. CD99 engagement: An effective therapeutic strategy for Ewing tumors. Cancer Res 2000;60:5134-5142.
18. Donnenberg AD, Donnenberg VS. Rare-event analysis in flow cytometry. Clin Lab Med 2007;27:627-652, viii.
19. Yaniv I, Stein J, Luria D, et al. Ewing sarcoma tumor cells express CD34: Implications for autologous stem cell transplantation. Bone Marrow Transplant 2007;39:589-594.
20. ShahVO, Civin CI, Loken MR. Flowcytometric analysis of human bone marrow. IV. Differential quantitative expression of T-200 common leukocyte antigen during normal hemopoiesis. J Immunol 1988;140:1861-1867.
21. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-791.
22. Cristofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005;23:1420-1430.
23. Kollermann J,Weikert S, Schostak M, et al. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. J Clin Oncol 2008;26:4928-4933.
24. Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007;450:1235-1239.
25. Pachmann K, Camara O, Kavallaris A, et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol 2008;26:1208-1215.